Our antibody oligonucleotide conjugate development services provide end-to-end support for pharmaceutical and biotech companies developing targeted AOC therapeutics. We combine antibody engineering, linker design, oligonucleotide chemistry, and advanced bioconjugation to deliver scalable, high-quality constructs for preclinical and early clinical programs.
We support a full range of bioconjugation strategies, including stochastic lysine and cysteine approaches as well as site-specific enzymatic, glycoconjugation, and click chemistry methods. These technologies enable precise control over conjugation, improving homogeneity, stability, and site-specific performance.
Our team designs and synthesizes both cleavable and non-cleavable linkers optimized for intracellular release and endosomal escape. We support multiple oligonucleotide modalities, including siRNA, antisense oligonucleotides, gapmers, and splice-switching oligos, with the ability to develop custom oligo chemistries and immune-modulating conjugates.
Our analytical platform provides comprehensive characterization, including DAR determination, conjugation-site analysis, free oligonucleotide quantification, oligo integrity, and nuclease and serum stability testing. Functional assays such as binding (EC50), internalization, endosomal escape, cytotoxicity, and PK/PD studies support candidate selection and mechanism validation.
We offer small-scale and pilot-scale (liter-scale) bioconjugation, along with cGMP payload and linker production where required. Our closed, automated workflows integrate conjugation, purification, and tangential flow filtration (TFF) into a single controlled process to improve efficiency, product consistency, and operator safety.
Our integrated CDMO model brings together antibody production, oligonucleotide synthesis, linker and payload development, conjugation, analytics, and fill-finish services in one streamlined workflow. This reduces transfer risk, shortens timelines, and simplifies supply chain complexity.
We also support method transfer and scale-up from early discovery through pilot batches and larger manufacturing. Our facilities and documentation are designed to meet regulatory expectations and support clinical supply and program progression.
Learn more about our pharmaceutical development services:
https://synergybioscience.com/pharmaceutical-development-services/